• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.应用急性肾损伤的新诊断标准,以方便在使用万古霉素治疗的患者中早期识别肾毒性。
Antimicrob Agents Chemother. 2011 Jul;55(7):3278-83. doi: 10.1128/AAC.00173-11. Epub 2011 May 16.
2
Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria.使用更新的急性肾损伤诊断标准定义的两性霉素B肾毒性的发病率、预测因素及其对医院死亡率的影响。
Antimicrob Agents Chemother. 2015 Aug;59(8):4759-69. doi: 10.1128/AAC.00525-15. Epub 2015 May 26.
3
Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria.危重症患者急性肾损伤的发病率、发生时间和结局因所采用的定义以及尿量标准的增加而有所不同。
BMC Nephrol. 2017 Feb 20;18(1):70. doi: 10.1186/s12882-017-0487-8.
4
Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?哌拉西林/他唑巴坦联合万古霉素的肾毒性:是否需要关注?
Int J Antimicrob Agents. 2018 Aug;52(2):180-184. doi: 10.1016/j.ijantimicag.2018.03.024. Epub 2018 Apr 9.
5
Acute kidney injury during daptomycin versus vancomycin treatment in cardiovascular critically ill patients: a propensity score matched analysis.心血管危重症患者使用达托霉素与万古霉素治疗期间的急性肾损伤:倾向评分匹配分析。
BMC Infect Dis. 2019 May 20;19(1):438. doi: 10.1186/s12879-019-4077-1.
6
Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.万古霉素联合哌拉西林-他唑巴坦或头孢吡肟治疗期间的肾毒性。
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.02089-16. Print 2017 Feb.
7
AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions.住院儿童急性肾损伤:比较pRIFLE、AKIN及KDIGO诊断标准
Clin J Am Soc Nephrol. 2015 Apr 7;10(4):554-61. doi: 10.2215/CJN.01900214. Epub 2015 Feb 3.
8
Subtle change of cystatin C, with or without acute kidney injury, associated with increased mortality in the intensive care unit.胱抑素 C 的细微变化,无论是否伴有急性肾损伤,都与重症监护病房的死亡率升高相关。
J Crit Care. 2011 Dec;26(6):566-71. doi: 10.1016/j.jcrc.2011.01.004. Epub 2011 Mar 21.
9
Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.抗菌药物降阶梯治疗策略对重症监护病房患者急性肾损伤的影响
Clin Infect Dis. 2019 Apr 24;68(9):1456-1462. doi: 10.1093/cid/ciy724.
10
Vancomycin-induced acute kidney injury in elderly Chinese patients: a single-centre cross-sectional study.万古霉素诱导的老年中国患者急性肾损伤:一项单中心横断面研究。
Br J Clin Pharmacol. 2018 Aug;84(8):1706-1718. doi: 10.1111/bcp.13594. Epub 2018 May 24.

引用本文的文献

1
Post-treatment late and long-term effects in bone sarcoma: A scoping review.骨肉瘤治疗后的晚期和长期影响:一项范围综述。
J Bone Oncol. 2025 Mar 21;52:100671. doi: 10.1016/j.jbo.2025.100671. eCollection 2025 Jun.
2
Impact of vancomycin area under the curve in early or later phase on efficacy and nephrotoxicity in patients with enterococcal bloodstream infections: a multicenter study.万古霉素曲线下面积在早期或晚期对肠球菌血流感染患者疗效及肾毒性的影响:一项多中心研究
BMC Infect Dis. 2025 Jan 28;25(1):133. doi: 10.1186/s12879-024-10399-9.
3
Therapeutic Interventions for Infections in Cystic Fibrosis Patients: A Review of Phase IV Trials.囊性纤维化患者感染的治疗干预措施:IV期试验综述
J Clin Med. 2024 Oct 30;13(21):6530. doi: 10.3390/jcm13216530.
4
Vancomycin area under the curve/minimum inhibitory concentration and trough level concordance-evaluation on an urban health unit.城市卫生单位中万古霉素曲线下面积/最低抑菌浓度与谷浓度的一致性评估
Ther Adv Infect Dis. 2022 Nov 28;9:20499361221140368. doi: 10.1177/20499361221140368. eCollection 2022 Jan-Dec.
5
The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the Food and Drug Administration's Adverse Event Reporting System (FAERS) Database.抗生素相关性急性肾损伤的风险及临床意义:对来自美国食品药品监督管理局不良事件报告系统(FAERS)数据库中有信号的药物临床数据的综述
Antibiotics (Basel). 2022 Oct 6;11(10):1367. doi: 10.3390/antibiotics11101367.
6
Evaluation of Vancomycin Accumulation in Patients With Obesity.肥胖患者万古霉素蓄积情况的评估
Open Forum Infect Dis. 2022 Sep 21;9(10):ofac491. doi: 10.1093/ofid/ofac491. eCollection 2022 Oct.
7
Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.耐甲氧西林金黄色葡萄球菌菌血症致肾毒性的危险因素:CAMERA2 试验的事后分析。
Clin Drug Investig. 2023 Jan;43(1):23-33. doi: 10.1007/s40261-022-01204-z. Epub 2022 Oct 10.
8
Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant Endovascular Infections?步入65岁:是时候考虑停用万古霉素治疗耐甲氧西林血管内感染了吗?
Open Forum Infect Dis. 2022 Apr 9;9(5):ofac137. doi: 10.1093/ofid/ofac137. eCollection 2022 May.
9
The impact of early target attainment of vancomycin in critically ill patients with confirmed Gram-positive infection: A retrospective cohort study.重症确诊革兰阳性感染患者早期达到万古霉素目标治疗的影响:一项回顾性队列研究。
BMC Infect Dis. 2021 Nov 24;21(1):1182. doi: 10.1186/s12879-021-06840-y.
10
Serum 5-Hydroxyindoleacetic Acid and Ratio of 5-Hydroxyindoleacetic Acid to Serotonin as Metabolomics Indicators for Acute Oxidative Stress and Inflammation in Vancomycin-Associated Acute Kidney Injury.血清5-羟吲哚乙酸及5-羟吲哚乙酸与血清素的比值作为万古霉素相关性急性肾损伤中急性氧化应激和炎症的代谢组学指标
Antioxidants (Basel). 2021 Jun 2;10(6):895. doi: 10.3390/antiox10060895.

本文引用的文献

1
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.万古霉素相关性肾毒性:高剂量治疗的风险评估。
Int J Antimicrob Agents. 2011 Feb;37(2):95-101. doi: 10.1016/j.ijantimicag.2010.10.013. Epub 2010 Dec 3.
2
Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2.比较 CKD 流行病学协作组(CKD-EPI)和肾脏病饮食改良研究(MDRD)方程在估计肾小球滤过率(GFR)水平在 60 mL/min/1.73 m2 以上的表现。
Am J Kidney Dis. 2010 Sep;56(3):486-95. doi: 10.1053/j.ajkd.2010.03.026. Epub 2010 Jun 16.
3
Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?万古霉素相关性肾毒性:严重关切还是人格谋杀?
Am J Med. 2010 Feb;123(2):182.e1-7. doi: 10.1016/j.amjmed.2009.05.031.
4
Clinical review: RIFLE and AKIN--time for reappraisal.临床综述:RIFLE和AKIN——重新评估的时候了。
Crit Care. 2009;13(3):211. doi: 10.1186/cc7759. Epub 2009 Jun 25.
5
Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.万古霉素对心脏手术后重症患者肾功能的影响:持续输注与间歇输注对比
Anesthesiology. 2009 Aug;111(2):356-65. doi: 10.1097/ALN.0b013e3181a97272.
6
Early diagnosis of acute kidney injury: the promise of novel biomarkers.急性肾损伤的早期诊断:新型生物标志物的前景。
Blood Purif. 2009;28(3):165-74. doi: 10.1159/000227785. Epub 2009 Jul 8.
7
Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis.急性肾损伤后死亡及其他不良结局的长期风险:一项系统评价与荟萃分析
Am J Kidney Dis. 2009 Jun;53(6):961-73. doi: 10.1053/j.ajkd.2008.11.034. Epub 2009 Apr 5.
8
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.成人患者万古霉素的治疗监测:美国卫生系统药师协会、美国传染病学会和传染病药师协会的共识综述
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. doi: 10.2146/ajhp080434.
9
Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.基因表达分析揭示了万古霉素诱导肾毒性的新潜在机制,并确定了候选基因标志物。
Toxicol Sci. 2009 Jan;107(1):258-69. doi: 10.1093/toxsci/kfn203. Epub 2008 Oct 16.
10
Biomarkers of acute kidney injury.急性肾损伤的生物标志物
Annu Rev Pharmacol Toxicol. 2008;48:463-93. doi: 10.1146/annurev.pharmtox.48.113006.094615.

应用急性肾损伤的新诊断标准,以方便在使用万古霉素治疗的患者中早期识别肾毒性。

Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.

机构信息

Huntington Hospital, Pasadena, California, USA.

出版信息

Antimicrob Agents Chemother. 2011 Jul;55(7):3278-83. doi: 10.1128/AAC.00173-11. Epub 2011 May 16.

DOI:10.1128/AAC.00173-11
PMID:21576448
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3122454/
Abstract

Acute kidney injury (AKI) associated with high-dose vancomycin (VAN) therapy is a clinical concern, but no uniform diagnostic criteria exist. The AKI Network (AKIN) proposed new criteria to diagnose AKI based on abrupt changes in serum creatinine or urine output. We conducted a prospective observational study to determine the incidence and severity of AKI and associated outcomes using the AKIN criteria versus traditional definitions. Eligible patients (n = 227) were elderly (median, 70 years) and received VAN therapy for 8 days (median). AKI occurred in 43 patients (19%) using AKIN criteria at an onset of 6 days. AKI incidence was similar for patients with a trough level of ≥15 (24%; 17/72) versus <15 (17%; 26/155) μg/ml. Compared to non-AKI patients, more AKI patients resided in the intensive care unit (ICU) (47% [20/43] versus 27% [50/184]; P = 0.017), had a prior AKI episode (19% [8/43] versus 7% [5/184]; P = 0.001), and received vasopressor (28% [12/43] versus 14% [25/184]; P = 0.04) and/or nephrotoxins (84% [36/43] versus 67% [123/184]; P = 0.04). Seventeen of the AKI patients met traditional criteria, of whom more patients had stage 2 and 3 AKI (76% versus 8%; P = 0.0001), dosage adjustment (41% versus 15%) and renal consultation (35% versus 12%), prolonged length of stay after AKI (11 versus 7.5 days) and died (29% versus 12%) than those diagnosed by AKIN criteria (P value not significant). Use of AKIN criteria for AKI has the potential to improve care of VAN-treated patients by facilitating early detection of AKI and warrants confirmation in large prospective trials.

摘要

高剂量万古霉素(VAN)治疗相关的急性肾损伤(AKI)是一个临床关注的问题,但目前尚无统一的诊断标准。AKI 网络(AKIN)提出了基于血清肌酐或尿量突然变化来诊断 AKI 的新标准。我们进行了一项前瞻性观察研究,使用 AKIN 标准和传统定义来确定 AKI 的发生率和严重程度以及相关结局。符合条件的患者(n=227)年龄较大(中位数 70 岁),接受 VAN 治疗 8 天(中位数)。使用 AKIN 标准,43 名患者(19%)在第 6 天发生 AKI。VAN 谷浓度≥15μg/ml(24%;17/72)和<15μg/ml(17%;26/155)的患者 AKI 发生率相似。与非 AKI 患者相比,更多 AKI 患者入住重症监护病房(ICU)(47%[20/43]比 27%[50/184];P=0.017),有既往 AKI 病史(19%[8/43]比 7%[5/184];P=0.001),接受血管加压素(28%[12/43]比 14%[25/184];P=0.04)和/或肾毒性药物(84%[36/43]比 67%[123/184];P=0.04)治疗。AKI 患者中有 17 名符合传统标准,其中更多患者发生 2 期和 3 期 AKI(76%比 8%;P=0.0001),需要调整剂量(41%比 15%)和肾脏咨询(35%比 12%),AKI 后住院时间延长(11 天比 7.5 天)和死亡(29%比 12%)比 AKIN 标准诊断的患者更多(P 值无统计学意义)。使用 AKIN 标准诊断 AKI 有可能通过早期发现 AKI 改善 VAN 治疗患者的治疗效果,值得在大型前瞻性试验中进一步验证。